

## **Press Release**

# Nicox: Half-year liquidity contract statement for NICOX

July 5, 2022 – release at 7:30 am CET Sophia Antipolis, France

Under the liquidity contract entered into between NICOX and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30<sup>th</sup>, 2022:

- 233.609 shares
- € 106.207.47
- Number of executions on buy side on semester: 526
- Number of executions on sell side on semester: 571
- Traded volume on buy side on semester: 336,531 shares for € 706,259.94
- Traded volume on sell side on semester: 314,889 shares for € 660,405.27

#### As a reminder:

- the following resources appeared on the last half year statement on 31 December 2021 on the liquidity account:
- 211,967 shares
- € 152,371.09
- Number of executions on buy side on semester: 786
- Number of executions on sell side on semester: 728
- Traded volume on buy side on semester: 387,737 shares for € 1,278,136.61
- Traded volume on sell side on semester: 394,689 shares for € 1,304,467.12
- the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 500,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.



	Buy 3lde			Bell Side			
	Number of executions	Number of chares	Traded volume in EUR	Number of executions	Number of chares	Traded volume In EUR	
Total	528	338,631	708,259.84	671	314,889	680,405.27	
03/01/2022				17	8,000	21,040.00	
04/01/2022	4	4.000	10.360.00	9	4,000	10,600.00	
05/01/2022				22	22,000	60,720.00	
06/01/2022	1	1	2.77				
07/01/2022	13	9,000	24,750.00				
10/01/2022	4	4.000	10,880.00	3	2.000	5,600.00	
11/01/2022		4,000	10,000.00	7	3,137	8,595.38	
12/01/2022	4	2,000	5,500.00	10	3,863	10,739.14	
13/01/2022	8	5,000	13,650.00				
14/01/2022	16	5,000	13,650.00	1	13	36.14	
17/01/2022	- 10	10,000	12,000.00	10	2,000	5,500.00	
18/01/2022	3	3,000	8,160.00	- 10	2,000	0,000.00	
19/01/2022	3	5,000	13,500.00				
20/01/2022	2	3,000	8,070.00	1	1	2.72	
	10		27.234.05	- '	- 1	2.12	
21/01/2022		10,277					
24/01/2022	34	20,000	50,600.00				
25/01/2022		3,637	8,692.43				
26/01/2022	6	5,000	11,750.00				
27/01/2022	4	3,000	6,960.00	-			
28/01/2022	3	2,000	4,600.00	-	-		
31/01/2022	5	2,000	4,620.00				
01/02/2022	7	5,000	11,400.00	5	4,000	9,320.00	
02/02/2022				18	12,050	28,197.00	
03/02/2022	10	6,745	15,513.50	3	1,951	4,584.85	
04/02/2022	12	7,255	16,178.65	1	1	2.33	
07/02/2022	3	2,000	4,400.00	2	2,000	4,500.00	
08/02/2022	1	1,000	2,180.00	13	13,745	31,888.40	
09/02/2022	1	1,000	2,180.00				
10/02/2022	14	6,000	12,960.00	1	900	1,980.00	
11/02/2022	6	3,000	6,420.00	- 6	4,000	8,640.00	
14/02/2022	8	5,000	10,450.00				
15/02/2022	-	-		28	14,350	30,565.50	
16/02/2022	2	1,000	2,140.00	9	5,950	12,852.00	
17/02/2022	8	8,000	16,720.00		-		
18/02/2022	7	3,000	6,090.00		-		
23/02/2022	5	4,000	8,400.00	22	17,101	36,596.14	
24/02/2022	14	6,000	12,120.00				
25/02/2022				- 6	7,000	14,490.00	
28/02/2022	2	1,553	3,199.18	11	4,044	8,573.28	
01/03/2022	8	8,446	17,652.14	14	8,053	17,313.95	
02/03/2022	7	5,000	10,400.00	1	1	2.15	
03/03/2022	14	9,000	18,360.00		-		
04/03/2022	14	10,000	19,400.00				
07/03/2022	7	3,000	5,670.00				
08/03/2022	5	3,500	6,300.00	6	3,000	5,520.00	
09/03/2022				12	20,069	37,529.03	
10/03/2022				11	10,051	19,297.92	
11/03/2022				14	9,045	17,637.75	
14/03/2022	1	744	1,502.88	5	4,000	8,080.00	
15/03/2022	12	7,296	14,149.20				
16/03/2022	1	1,000	1,980.00	9	6,000	12,000.00	



	Buy 3lde			Sell Side		
	Number of anothorse	Number of chares	Traded volume In EUR	Number of executions	Number of chares	Traded volume In EUR
Total	628	338,631	708,259.94	671	314,889	680,405.27
17/03/2022	2	2,000	3,940.00	-		
18/03/2022	-			5	4,000	8,080.00
21/03/2022				5	3,602	7,348.08
22/03/2022				5	2,398	5,083.76
23/03/2022	5	2,000	4,020.00	-	-	
24/03/2022	1	1,000	1,980.00	-	-	
25/03/2022	2	2,000	3,900.00			
28/03/2022	11	6,000	11,760.00	6	6,000	12,540.00
29/03/2022	10	7,044	13,876.68	14	9,000	18,090.00
30/03/2022	3	2,000	3,940.00	2	2,000	4,020.00
31/03/2022	6	3,000	5,940.00			
01/04/2022	2	1,969	3,839.55	2	1,000	1,980.00
04/04/2022	3	2,000	3,900.00	1	15	29.85
05/04/2022	1	1,000	1,950.00	3	1,985	3,910.45
06/04/2022	16	6,103	11,595.70	-	-,	
07/04/2022	11	11,000	20,130.00	13	7,000	13,440.00
08/04/2022	- 11	9,000	15,480.00	6	2.000	3,600.00
11/04/2022	5	4,000	6.920.00	17	11,000	19,470.00
12/04/2022	7	4,000	6.880.00	7	6,000	10,580.00
13/04/2022	6	2,000	3,540.00		0,000	70,000.00
14/04/2022	6	4,000	7,000.00		-	
19/04/2022	3	2,000		1	1,000	1,720.00
20/04/2022	2	2,000	3,420.00	-	1,000	1,120.00
21/04/2022		2,000	3,420.00	1	1,000	1,720.00
22/04/2022	1	1,000		3	1,001	
	3		1,680.00	2		1,741.74
25/04/2022	6	2,000	3,340.00	1	1,000	1,680.00
27/04/2022	1	1,000			-	1,700.00
28/04/2022			1,680.00		2.077	6.000.67
			-	9	3,877	6,629.67
29/04/2022		-		1	1	1.74
02/05/2022			-	5	2,121	3,711.75
03/05/2022		2.000	400400	18	8,014	14,585.48
04/05/2022	4	2,200	4,004.00	2	520	972.40
05/05/2022	5	1,800	3,222.00	1	1	1.85
08/05/2022	5	3,013	5,272.75	3	3,001	5,431.81
09/05/2022	1	1,000	1,800.00	3	1,999	3,658.17
10/05/2022	4	2,938	5,317.78	1	1,000	1,860.00
11/05/2022	10	3,062	5,480.98			
12/05/2022	4	3,987	6,817.77	2	2	3.50
13/05/2022				- 8	1,999	3,458.27
16/05/2022				4	1,999	3,538.23
17/05/2022				1	1	1.80
18/05/2022				4	2,999	5,458.18
19/05/2022				5	3,000	5,460.00
20/05/2022	1	115	209.30	7	4,000	7,440.00
23/05/2022	2	1,000	1,840.00	2	1,000	1,880.00
24/05/2022	9	4,907	8,881.67	-	-	
25/05/2022	4	1,978	3,501.06	1	50	90.00
26/05/2022	4	2,000	3,500.00	67	1,001	1,781.78
27/05/2022				4	3,949	7,187.18
30/05/2022	5	880	1,619.20	3	2,000	3,700.00



	Buy 3lde				Sell Side		
	Number of executions	Number of shares	Traded volume in EUR		Number of executions		
Total	628	338,631	708,259.94		671	671 314,889	
31/05/2022	6	5,120	9,164.80		1	1 898	
01/06/2022		-			3	3 1,000	
02/06/2022					2	2 102	
03/06/2022					7	7 3,000	
06/06/2022	1	1,000	1,820.00		2	2 201	
07/06/2022	1	1,000	1,810.00				
08/06/2022					5	5 2,799	
09/06/2022	1	1,000	1,840.00				
0/06/2022	1	1,000	1,820.00		-		
13/06/2022	8	6,000	10,560.00		1	1 1,000	
14/06/2022	4	2,000	3,460.00	2		1,050	
15/06/2022	2	1,000	1,760.00	1		1	
16/06/2022	3	3,000	5,160.00	2		1,000	
20/06/2022	-	-		5		2,160	
21/06/2022	-	-		B.		2,789	
22/06/2022	2	1,000	1,780.00	-			
23/06/2022	3	3,000	5,370.00	2		1,001	
24/06/2022	2	90	162.00	-		-	
27/06/2022		-		5		1,450	
28/06/2022	1	1	1.85	2		550	
29/06/2022	2	911	1,639.80	1		28	
30/06/2022	12	6,999	12,248.25	-			

### **About Nicox**

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox's lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone propionate, for dry eye disease. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

#### **Analyst coverage**

Bryan, Garnier & Co Edison Investment Research H.C. Wainwright & Co Kepler Cheuvreux Dylan van Haaften Pooya Hemami Yi Chen Arsene Guekam Paris, France London, UK New York, U.S. Paris, France



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.



#### Contacts

#### **Nicox**

Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com

### **Forward-Looking Statements**

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 3<sup>rd</sup> chapter of the 'Document d'enregistrement universel, rapport financier annuel et rapport de gestion 2021' filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 which is available on Nicox's website (<a href="https://www.nicox.com">www.nicox.com</a>).

#### Nicox S.A.

Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99